Summary Using rat glioma C6 cells as a model, we have found a bimodal effect of a-thrombin on cell growth. In C6 cells treated with a-thrombin at concentrations from 0.02 nm to 1.0 nm, inhibition of cell proliferation was noted. Because the thrombin receptor agonist peptide TRAP-6 also induced inhibition of cell proliferation and the thrombin receptor antagonist peptide Ti prevented the inhibitory effect of athrombin on C6 glioma cell growth, thrombin receptor involvement in antiproliferative action of a-thrombin in C6 glioma cells is highly likely. However, stimulation of cell proliferation observed when C6 cells were treated with a-thrombin at higher doses (> 1.0 nM) seems to be mediated by as yet undefined thrombin receptor-independent biochemical mechanisms.
Thrombin evokes biological responses from a variety of cells, including platelets (Bemdt and Philipps, 1981) , fibroblasts, vascular smooth muscle cells (Glenn et al, 1980) and monocytes (Bar-Shavit et al, 1983) . These effects are known to be mediated by the activation of thrombin receptors in these cells. The thrombin receptor belongs to the family of G-protein-coupled receptors. Thrombin binds to this receptor and cleaves it in the amino-terminal portion. This cleavage event unmasks a new amino terminus that then functions as a 'tethered peptide ligand', binding to the thrombin receptor in specific regions to cause receptor activation. Synthetic peptides of 5-14 amino acids (thrombin receptor-activating peptides, TRAPs), corresponding to the tethered ligand sequence, were found to be agonists for receptor activation (Vu et al, 1991; Nanevicz et al, 1995) .
Thrombin is a well-studied mitogen for a variety of cell types (Chen and Buchanan, 1975; Camey et al, 1985) and it seems to play a role in tumour growth (Zacharski, 1987; Nierodzik et al, 1992) . Recently, the presence of 'tethered ligand' thrombin receptor in carcinosarcoma and melanoma cells has been shown, and its biological function has been suggested (Wojtukiewicz et al, 1995) . However, the role of thrombin and the 'tethered ligand' thrombin receptor in tumour cell metabolism is still undefined.
Rat glioma C6 cells, a widely used model in neurobiological studies, are known to respond to thrombin with morphological changes (Tas and Koschel, 1990) , and thrombin receptor-mediated transmembrane signalling has been investigated (Turner et al, 1994; Czubayko and Reiser, 1995; Kaufmann et al, 1996) . Moreover, this tumour cell line has been frequently used in the investigation of glioma cell growth (Barg et al, 1994; Strawn et al, 1994; Takano et al, 1994) .
In this study, we assessed the effects of a-thrombin on cell proliferation in rat glioma C6 cells by the estimation of [3H]thymidine incorporation and the increase in cell number. The results demonstrate that a-thrombin has opposite effects on glioma cell growth.
MATERIALS AND METHODS
Human a-thrombin (3700 NIH-U mg-' protein) was purchased from Sigma Chemicals (Deisenhofen, Germany), [methyl-3H] a-Thrombin (nM) Figure 1 [3H]thymidine incorporation into DNA in C6 rat glioma cells exposed to a-thrombin. Cells were stimulated with a-thrombin for 24 h. Figure 1 , the application of athrombin at concentrations < 1.0 nm resulted in the inhibition of [3H]thymidine incorporation. The effect was obtained with a threshold concentration of 0.02 nM a-thrombin (Figure 1 ). Maximal inhibition was seen after exposure of C6 glioma cells with 0.07 nM a-thrombin (Figure 1) . As further shown in Figure 1 , at concentrations > 1.0 nM, a-thrombin stimulated DNA synthesis in C6 glioma cells.
In a further series of experiments, we investigated the participation of thrombin receptor activation in a-thrombin-induced effects on [3H]thymidine incorporation in C6 cells. First, TRAP-6 was shown dose dependently to induce inhibition of [3H]thymidine incorporation in C6 glioma cells (Figure 2) . Then, we investigated the effect of the thrombin receptor antagonist Met-Ser-Arg-ProAla-Cys-Pro-Asn-Asp-Lys-Tyr-Glu (peptide T1) on a-thrombinand TRAP-induced effects on DNA synthesis in C6 cells. When C6 cells were preincubated with the thrombin receptor antagonist for 30 min, the inhibitory action of a-thrombin on DNA synthesis in C6 glioma cells could be completely blocked (Figure 3) . (Figure 3 ). In addition, the thrombin receptor antagonist peptide TI (1.0 ,UM) could prevent the TRAP-6 induced effects on [3H]thymidine incorporation in C6 glioma cells (Figure 3) .
Moreover, in C6 cells treated with the thrombin inhibitor hirudin (50 nM) thrombin-induced inhibition or stimulation of DNA synthesis could no longer be observed. But hirudin was unable to abrogate the TRAP-6 induced inhibition of [3H]thymidine incorporation in C6 glioma cells (data not shown).
British Journal of Cancer (1997) 76(12) In a further experimental setup, we assessed the effect of athrombin on cell proliferation by determining the increase in cell number. The application of a-thrombin at concentrations from 0.02 nm to 1.0 nm significantly reduced the proliferation of C6 cells as shown in Figure 4 for the treatment of C6 cells with 0.1 nM a-thrombin. This effect could be completely blocked by peptide TI (Figure 4) . In contrast to this, higher concentrations of athrombin (> 1.0nM) enhanced C6 cell proliferation, compared with non-stimulated C6 cells. 
DISCUSSION
Rat glioma C6 cells are a widely used model in neurobiology, but this tumour cell line may also be used as a model in studying brain cancer.
In this study, we investigated the effect of a-thrombin on cell proliferation in C6 cells by measurement of DNA synthesis and counting of cell number. Inhibition of [3H]thymidine incorporation and a significantly reduced cell number were noted when C6 cells were treated with low doses of a-thrombin or TRAP-6. Together with the finding that peptide TI completely blocked the athrombin and TRAP-6-induced effect on decreased [3H]thymidine incorporation and cell number in C6 glioma cells it seems to be very likely that a 'tethered ligand' thrombin receptor is involved in the inhibitory effects of thrombin on cell proliferation in C6 cells. However, other biochemical mechanisms seem to contribute to the proliferative effect at higher doses of thrombin (> 1.0 nM) in C6 cells. This suggestion was supported by the observation that the thrombin receptor peptide Ti was unable to prevent the effects of thrombin at higher doses on cell proliferation in C6 cells.
Our results demonstrate for the first time a bimodal role of athrombin as both a negative and a positive regulator of tumour cell growth. Therefore, C6 cells seem to be a very interesting model for studying the function of thrombin in brain tumour growth. In C6 cells, the antiproliferative action of a-thrombin at lower doses seems to be mediated by the 'tethered ligand' thrombin receptor. This part of a-thrombin action in C6 glioma is in line with the situation found in megakaryocytic cells, in which involvement of thrombin receptor activation in an antiproliferative action of thrombin has been demonstrated by Plantier et al (1994) . However, there must be other mechanisms that contribute to the increase in [3H]thymidine incorporation and enhanced cell number in C6 glioma observed when a-thrombin was added at concentrations > 1.0 nm. We found in our investigations that the thrombin inhibitor hirudin blocked both the thrombin-induced inhibition and stimulation of [3H]thymidine incorporation in C6 glioma cells. Because hirudin is known to bind very tightly not only to the catalytic site, but also to other sites outside the active site (exosite I, substrate recognition site, Rydel et al, 1990) in the thrombin molecule, involvement of these non-catalytic binding sites in the proliferative action of a-thrombin in C6 glioma cells seems to be possible. Moreover, it is known that the non-catalytic action of thrombin may result in enhanced mitogenesis in different cell types (Hollenberg, 1996) and thrombin was shown to induce growth of the endothelial HUVEC cell line via dual-signalling pathways, with one of them seemingly being mediated by nonproteolytic actions (Herbert et al, 1994) .
Further investigations are in progress to clarify whether such non-proteolytic processes participate in the proliferative effects of thrombin in C6 rat glioma cells.
